{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:21:42Z","timestamp":1790162502321,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12967-019-2012-2","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T08:04:45Z","timestamp":1565769885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["New paradigm for stage III melanoma: from surgery to adjuvant treatment"],"prefix":"10.1186","volume":"17","author":[{"given":"Paolo Antonio","family":"Ascierto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Borgognoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mocellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Patuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Stanganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Carac\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"issue":"6","key":"2012_CR1","doi-asserted-by":"publisher","first-page":"472e92","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, For members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform, et al. Melanoma staging: Evidencebased changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472e92.","journal-title":"CA Cancer J Clin"},{"key":"2012_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2017.11.023","volume":"91","author":"JJ Grob","year":"2018","unstructured":"Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, et al. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. Eur J Cancer. 2018;91:168\u201370.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2012_CR3","doi-asserted-by":"publisher","first-page":"757e67","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, German Dermatologic Cooperative Oncology Group (DeCOG), et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757e67.","journal-title":"Lancet Oncol"},{"issue":"23","key":"2012_CR4","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"2012_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med"},{"key":"2012_CR6","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med"},{"issue":"19","key":"2012_CR7","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med"},{"key":"2012_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2018.02.022","volume":"96","author":"D Verver","year":"2018","unstructured":"Verver D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, et al. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. Eur J Cancer. 2018;96:25\u201333.","journal-title":"Eur J Cancer"},{"key":"2012_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejca.2017.09.002","volume":"87","author":"MF Madu","year":"2017","unstructured":"Madu MF, Franke V, Bruin MM, Berger DMS, Bierman C, J\u00f3\u017awiak K, et al. Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria. Eur J Cancer. 2017;87:212\u20135. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.09.002\n                    \n                  .","journal-title":"Eur J Cancer"},{"issue":"1","key":"2012_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1245\/s10434-017-6143-5","volume":"25","author":"CR Rossi","year":"2018","unstructured":"Rossi CR, Mocellin S, Campana LG, Borgognoni L, Sestini S, Giudice G, Italian Melanoma Intergroup (IMI), et al. Prediction of non-sentinel node status in patients with melanoma and positive sentinel node biopsy: an italian melanoma intergroup (IMI) study. Ann Surg Oncol. 2018;25(1):271\u20139.","journal-title":"Ann Surg Oncol"},{"key":"2012_CR11","first-page":"CD008955","volume":"6","author":"S Mocellin","year":"2013","unstructured":"Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. 2013;6:CD008955.","journal-title":"Cochrane Database Syst Rev"},{"key":"2012_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","volume":"82","author":"NJ Ives","year":"2017","unstructured":"Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, International Melanoma Meta-Analysis Collaborative Group (IMMCG), et al. Adjuvant interferon-\u03b1 for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017;82:171\u201383.","journal-title":"Eur J Cancer"},{"key":"2012_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel S, R\u00f6hmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247\u201357.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2012_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","volume":"19","author":"M Maio","year":"2018","unstructured":"Maio M, Lewis K, Demidov L, Mandal\u00e0 M, Bondarenko I, Ascierto PA, BRIM8 Investigators., et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19(4):510\u201320.","journal-title":"Lancet Oncol"},{"key":"2012_CR15","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.18.01219","volume":"36","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandal\u00e0 M, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol. 2018;36:3441\u20139.","journal-title":"J Clin Oncol"},{"issue":"19","key":"2012_CR16","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355.","journal-title":"N Engl J Med"},{"key":"2012_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejca.2019.05.020","volume":"116","author":"AMM Eggermont","year":"2019","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325\/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer. 2019;116:148\u201357. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2019.05.020\n                    \n                  .","journal-title":"Eur J Cancer"},{"issue":"9","key":"2012_CR18","doi-asserted-by":"publisher","first-page":"e1468955","DOI":"10.1080\/2162402X.2018.1468955","volume":"7","author":"PA Ascierto","year":"2018","unstructured":"Ascierto PA, Dummer R. Immunological effects of BRAF\u2009+\u2009MEK inhibition. Oncoimmunology. 2018;7(9):e1468955.","journal-title":"Oncoimmunology"},{"issue":"6","key":"2012_CR19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","volume":"248","author":"AC van Akkooi","year":"2008","unstructured":"van Akkooi AC, Nowecki ZI, Voit C, Sch\u00e4fer-Hesterberg G, Michej W, de Wilt JH, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg. 2008;248(6):949\u201355.","journal-title":"Ann Surg"},{"issue":"11","key":"2012_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11912-018-0733-7","volume":"20","author":"G Palmieri","year":"2018","unstructured":"Palmieri G, Colombino M, Casula M, Manca A, Mandal\u00e0 M, Cossu A, Italian Melanoma Intergroup (IMI). Molecular pathways in melanomagenesis: what we learned from next-generation sequencing approaches. Curr Oncol Rep. 2018;20(11):86. \n                    https:\/\/doi.org\/10.1007\/s11912-018-0733-7\n                    \n                  .","journal-title":"Curr Oncol Rep."},{"issue":"3","key":"2012_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40257-017-0260-6","volume":"18","author":"KG Griewank","year":"2017","unstructured":"Griewank KG, Schilling B. Next-generation sequencing to guide treatment of advanced melanoma. Am J Clin Dermatol. 2017;18(3):303\u201310. \n                    https:\/\/doi.org\/10.1007\/s40257-017-0260-6\n                    \n                  .","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"2012_CR22","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u201361.","journal-title":"Nat Med"},{"issue":"3","key":"2012_CR23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454\u201361.","journal-title":"Nat Med"},{"issue":"11","key":"2012_CR24","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649\u201354. \n                    https:\/\/doi.org\/10.1038\/s41591-018-0197-1\n                    \n                  .","journal-title":"Nat Med"},{"issue":"2","key":"2012_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","volume":"19","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018;19(2):181\u201393. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(18)30015-9\n                    \n                  .","journal-title":"Lancet Oncol."},{"issue":"11","key":"2012_CR26","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-018-0250-0","volume":"24","author":"C Robert","year":"2018","unstructured":"Robert C. Is earlier better for melanoma checkpoint blockade? Nat Med. 2018;24(11):1645\u20138. \n                    https:\/\/doi.org\/10.1038\/s41591-018-0250-0\n                    \n                  .","journal-title":"Nat Med"},{"issue":"15 suppl","key":"2012_CR27","doi-asserted-by":"publisher","first-page":"e21032","DOI":"10.1200\/JCO.2016.34.15_suppl.e21032","volume":"34","author":"KF Grossmann","year":"2017","unstructured":"Grossmann KF, Othus M, Tarhini AA, Patel SP, Moon J, Sondak VK, et al. SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma. J Clin Oncol. 2017;34(15 suppl):e21032. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.e21032\n                    \n                  .","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1186\/s12967-019-2067-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000}}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2012-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-2012-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2012-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T23:21:08Z","timestamp":1597274468000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-2012-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2012"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-2012-2","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12967-019-2067-0","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"assertion":[{"value":"11 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1], the authors reported that one of the authors, Corrado Carac\u00f2, has been accidentally omitted from the author list. In this Correction the author has been added to the author list.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PAA has\/had a Consulting or Advisory Role for BMS, Roche-Genentech, MSD, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, Newlink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore. He received also Research funds from BMS, Roche-Genentech, Array, and travel support from MSD.PQ participated to Advisory Boards for Novartis, BMS, Merck. The other authors have no competing interests directly relevant to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}